Related content

A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

By  

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3481-3490

Blackwell Publishing

Access to resources Recommend Favorite

A phase I study of continuous infusion cilengitide in patients with solid tumors

By O'Donnell Peter  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 604-610

Springer Publishing Company

Access to resources Recommend Favorite

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

By Samol Jens  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1493-1500

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetics and Safety of Ebastine in Patients with Impaired Hepatic Function Compared with Healthy Volunteers: A Phase I Open-Label Study

By Lasseter K.C.  

Clinical Pharmacokinetics, Vol. 43, Iss. 2, 2004-01 ,pp. : 121-129

Adis International

Access to resources Recommend Favorite

Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D₃ analogue, in a phase I study of patients with advanced malignancies

By Wieder Robert   Novick Steven C.   Hollis Bruce W.   Bryan Margarette   Chanel Suzanne M.   Owusu Kate   Camastra Danielle   Saunders Tracie   Pliner Lillian   Harrison Jonathan   Bonate Peter   Williams Tom   Soignet Steven  

Investigational New Drugs, Vol. 21, Iss. 4, 2003-11 ,pp. : 445-452

Springer Publishing Company

Access to resources Recommend Favorite